Poslední aktualizace :
19/11/2024
Antiemetikum   Palonosetron hydrochloride  
injekce
Stabilita roztoků Stabilita směsí Faktory ovlivňující stabilitu Kompatibilita Způsoby aplikace Odkazy pdf
   Chemický vzorec  

Obchodní název   Obchodní název     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Aloxi äpanÏlsko, Belgie, Dánsko, Finsko, Irsko, Island, Itálie, Japonsko, Kanada, Lucembursko, Malajsie, MaÔarsko, NÏmecko, Nizozemsko, Norsko, Polsko, Portugalsko, Rakousko, Rumunsko, Švédsko, Švýcarsko, Turecko, USA, Velká Británie, ÿecko
Chepatron Indie
Cinvex Turecko
Factoket Mexiko
Lotisa Turecko
Onicit Chile, Ekvádor, Itálie, Kolumbie, Peru
Palohalt Chile, Peru
Paloject Turecko
Palonosetron äpanÏlsko, Belgie, Chile, Ekvádor, Francie, NÏmecko, Švýcarsko, Velká Británie
Palostar Indie
Palzen Indie
Vinaltro Mexiko
Viqet Mexiko
Vonaxi Turecko
Odkazy   injekce   Odkazy : Palonosetron hydrochloride  
typ uveřejnění
1932 noviny Trissel LA, Zhang Y.
Compatibility and stability of Aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate.
Int J Pharm Compound 2004 ; 8,5: 398-403.
1936 noviny Trissel LA, Xu QA.
Physical and chemical stability of palonosetron HCl in 4 infusion solusions.
Ann Pharmacotherapy 2004 ; 38: 1608-1611.
1940 noviny Xu QA, Trissel LA.
Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 1596-1598.
1950 noviny Trissel LA, Yanping Z.
Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration.
J Oncol Pharm Practice 2004 ; 10: 191-195.
1955 noviny Trissel LA, Zhang Y.
Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration.
Ann Pharmacotherapy 2005 ; 39: 280-283.
1975 noviny Trissel LA, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 9, 3: 235-237.
1976 noviny Trissel LA, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 9, 3: 238-241.
2009 noviny Trissel LA, Zhang Y.
Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 2005, 9, 4: 320-322.
2016 noviny Xu QA, Trissel LA.
Compatibility of palonosetron with cyclophosphamide and with ifosfamide during Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 1998-2000.
2107 noviny Trissel LA, Zhang Y, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration.
Int J Pharm Compound 2006 ; 10: 234-236.
2179 noviny Trusley C, Ben M, Kupiec TC, Trissel LA.
Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration.
Int J Pharm Compound 2007 ; 11, 1: 82-85.
2196 noviny Trissel LA, Trusley C, Ben M, Kupiec TC.
Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration.
Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213.
2214 noviny Ben M, Trusley C,Kupiec T.C, Trissel L.A.
Palonosetron hydrochloride compatibility and stability with three beta-lactam antibiotics during simulated Y-site administration.
Int J Pharm Compound 2007 ; 11, 6: 520-524.
2227 noviny Trusley C, Ben M, Kupiec TC, Trissel LA.
Compatibility and stability of palonosetron hydrochloride with four neuromuscular blocking agents during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12, 2: 156-160.
2228 noviny Kupiec T, Ben M, Trusley C, Trissel LA.
Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12,2: 170-173.
2279 noviny Kupiec T, Trusley C, Ben M, Trissel LA.
Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759.
2281 noviny Ben M, Kupiec T, Trusley C, Trisel LA.
Compatibility and stability of palonosetron hydrochloride with lactated Ringer's, Hetastarch in lactated electrolyte, an mannitol injections during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12, 5: 460-462.
2286 noviny Ben M, Trusley C, Kupiec TC, Trissel LA.
Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12, 4: 368-371.
2312 noviny Trissel L.A, Trusley C, Kupiec T.C, Ben M.
Compatibility and stability of palonosetron hydrochloride and propofol during simulated Y-site administration.
Int J Pharm Compound 2009 ; 13, 1: 78-80.
3459 noviny Sun S, Schaller J, Placek J, Duersch B.
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
Cancer Chemother Pharmacol 2013 ; 72: 509-513.
3928 noviny Wu G, Yeung S, Chen F.
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride.
Int J Pharm Compound 2017 ; 21, 1: 76-82.
3981 noviny He G, Zeng F, Lei K, Xia S, Deng L, Zhang C, Liu D.
Compatibility of dexamethasone sodium phosphate with 5-HT3 receptor antagonists in infusion solutions: a comprehensive study
EJHP 2017 ;24:162?166
4062 noviny Wu George, Powers Dan, Yeung S, Chen F, Neelon K.
Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous palonosetron hydrochloride injection and dexamethasone sodium phosphate injection.
Int J Pharm Compound 2018 ;22,1:76-85
4310 noviny Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M.
Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs.
Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.

  Mentions Légales